The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Sequential Immunization of Melanoma Patients with GD3 Ganglioside Vaccine and Anti-Idiotypic Monoclonal Antibody That Mimics GD3 Ganglioside
Open accessAbstract
GD3 ganglioside is an attractive target for immunotherapy of melanoma because it is abundantly expressed on all melanomas but not expressed on most normal tissues. Although GD3 has proven to be one of the least immunogenic gangliosides, our recent studies showed that anti-GD3 antibodies can be induced in patients immunized either with GD3-lactone-KLH (GD3-L-KLH) plus QS-21 adjuvant or with BEC2 anti-idiotypic monoclonal antibody vaccine, which mimics GD3, plus Bacillus Calmette-Guérin. We compared the immunogenicity of these two vaccines and tested whether one vaccine could prime an antibody response to the other. This is the first clinical trial immunizing patients with both antigen and anti-idiotypic monoclonal antibody vaccine. Twenty-four melanoma patients were randomized to be immunized with either BEC2 followed by GD3-L-KLH or in the opposite order. Our prior study suggested that a 25-microg dose of BEC2 was more immunogenic than our standard dose of 2.5 mg and therefore was used in this trial. Overall, 10 of 24 patients (42%) developed anti-GD3 antibodies detectable by ELISA, five in each cohort. All antibody responses were in response to the GD3-L-KLH vaccine. We found no evidence of priming by either vaccine. Antibody responses did not correlate with survival outcomes. Cellular responses were detected by enzyme-linked immunospot against BEC2, Bacillus Calmette-Guérin, and KLH, but not against GD3. We confirmed that GD3-L-KLH vaccine induces anti-GD3 antibodies, but we were unable to confirm our previous finding that a 25-microg dose of BEC2 is immunogenic. Future multivalent ganglioside vaccines should include the GD3-L-KLH vaccine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
Balch, C. M., Buzaid, A. C., Soong, S., Atkins, M. B., Cascinelli, N., Coit, D. G., Fleming, I. D., Gershenwald, J. E., Houghton, A. N., Kirkwood, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3635 · Cited by 2,627
Miyamoto, K., Miyake, S., & Yamamura, T. (2001) · Nature · doi:10.1038/35097097 · Cited by 879
Kensil, C. R., Patel, U., Lennick, M., & Marciani, D. J. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.2.431 · Cited by 659
Crystal Structure of Mouse CD1: An MHC-Like Fold with a Large Hydrophobic Binding Groove
Zeng, Z.-H., Castaño, A. R., Segelke, B. W., Stura, E. A., Peterson, P. A., & Wilson, I. A. (1997) · Science · doi:10.1126/science.277.5324.339 · Cited by 631
Prolonged IFN-γ–producing NKT response induced with α-galactosylceramide–loaded DCs
Fujii, S., Shimizu, K., Kronenberg, M., et al. (2002) · Nature Immunology · doi:10.1038/ni827 · Cited by 553
Cross-presentation of Disialoganglioside GD3 to Natural Killer T Cells
Wu, D., Segal, N. H., Sidobre, S., Kronenberg, M., & Chapman, P. B. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030446 · Cited by 279
Self-citationStein, K. E., & Söderström, T. (1984) · The Journal of Experimental Medicine · doi:10.1084/jem.160.4.1001 · Cited by 264
Structure of human CD1b with bound ligands at 2.3 Å, a maze for alkyl chains
Gadola, S. D., Zaccai, N. R., Harlos, K., Shepherd, D., Castro-Palomino, J. C., Ritter, G., Schmidt, R. R., Jones, E. Y., & Cerundolo, V. (2002) · Nature Immunology · doi:10.1038/ni821 · Cited by 259
Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses
Newman, M. J., Wu, J., Gardner, B. H., et al. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.8.2357 · Cited by 224
Active-specific immunotherapy for melanoma.
Mitchell, M. S., Harel, W., Kempf, R. A., et al. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.5.856 · Cited by 184
Immunogenicity of melanoma‐associated gangliosides in cancer patients
Tai, T., Cahan, L. D., Tsuchida, T., Saxton, R. E., Irie, R. F., & Morton, D. L. (1985) · International Journal of Cancer · doi:10.1002/ijc.2910350507 · Cited by 166
Livingston, P. O. (1995) · Immunological Reviews · doi:10.1111/j.1600-065x.1995.tb00080.x · Cited by 163
Self-citationSugiyama, K., Shimizu, M., Akiyama, T., Tamaoki, T., Yamaguchi, K., Takahashi, R., Eastman, A. R., & Akinaga, S. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000301)85:5 · Cited by 89
Ritter, G., Boosfeld, E., Adluri, R., et al. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910480312 · Cited by 76
Chapman, P. B., & Houghton, A. N. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115276 · Cited by 70
Self-citationChapman, P. B., Morrisey, D., Panageas, K. S., et al. (2000) · PubMed · Cited by 56
Self-citationYao, T., Meyers, M. L., Livingston, P. O., et al. (1999) · PubMed · Cited by 50
Self-citationRitter, G., Ritter‐Boosfeld, E., Adluri, R., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620604 · Cited by 42
Mouse Immunoglobulin Kappa Chain MPC 11: Extra Amino-Terminal Residues
Smith, G. P. (1973) · Science · doi:10.1126/science.181.4103.941 · Cited by 34
Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody.
Chapman, P. B. (2003) · PubMed · Cited by 32
Self-citationChapman, P. B., Williams, L. J., Salibi, N., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2003.12.028 · Cited by 32
Self-citationZakut, R., Cohen, J. B., & Givol, D. (1980) · Nucleic Acids Research · doi:10.1093/nar/8.16.3591 · Cited by 27
The CD1b structure: antigen presentation adapts to a high-fat diet
Niazi, K., Porcelli, S. A., & Modlin, R. L. (2002) · Nature Immunology · doi:10.1038/ni0802-703 · Cited by 6
Cited by
Sorted by citations
Teulings, H.-E., Limpens, J., Jansen, S. N., Zwinderman, A. H., Reitsma, J. B., Spuls, P. I., & Luiten, R. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4756 · Cited by 625
De Masi, R., & Orlando, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137373 · Cited by 20
“Thus, GD3 ganglioside vaccines and anti-idiotypic monoclonal antibodies, which mimic GD3 gangliosides, were carried out on melanoma patients with evidence of a low survival outcome [256].”
Background
Metadata
- Authors
- Chapman, P. B., Wu, D., Ragupathi, G., Lu, S., Williams, L., Hwu, W.-J., Johnson, D., & Livingston, P. O.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Clinical Cancer Research
- Published
- 2004-07-15
- Volume
- 10
- Issue
- 14
- Pages
- 4717-4723
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W1966719737
- Cited by
- 70
- References
- 23
- Citations by year
- 2026: 4 · 2024: 2 · 2022: 2 · 2021: 3 · 2019: 2 · 2017: 1 · 2015: 2 · 2014: 4 · 2013: 4 · 2012: 4
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health (5r21ca077624-02)
- National Cancer Institute (CA77624)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- GD3 ganglioside, melanoma, cancer immunotherapy, QS-21 adjuvant, BCG adjuvant, sequential vaccination, vaccine priming, antibody response, cell-mediated immunity, immunogenicity
- MeSH terms
- Adolescent, Adult, Antibodies, Anti-Idiotypic, BCG Vaccine, Enzyme-Linked Immunosorbent Assay, Female, Gangliosides, Humans, Immunoglobulin G, Immunization, Male, Melanoma, Middle Aged, Neoplasm Staging, T-Lymphocytes, Treatment Outcome, Vaccines, Conjugate, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
